MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Abrilumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 30 May 2018 Status changed from active, no longer recruiting to completed.
- 23 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Apr 2018.